A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2014
At a glance
- Drugs Tiagabine (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 25 Aug 2006 New trial record.